Overview

Phase 1 TAK-925 Study in Healthy Adult and Elderly Volunteers and Participants With Narcolepsy

Status:
Completed
Trial end date:
2018-09-04
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate safety, tolerability, and pharmacokinetics of TAK-925 when a single dose of TAK-925 is administered to healthy adult participants, healthy elderly participants and patients with type 1 narcolepsy.
Phase:
Phase 1
Details
Lead Sponsor:
Takeda